Key Takeaways VCYT is advancing its nasal swab NIGHTINGALE study and MRD platform for multi-tumor diagnostics. VCYT's Decipher test volumes rose 37% in Q1, with 85 studies backing its role in prostate cancer care. Veracyte is grappling with falling Biopharma revenues and cost pressures from macroeconomic headwinds.Veracyte (VCYT) is making solid progress in its long-term growth drivers, including in its NIGHTINGALE study for nasal swabs. The company’s Decipher franchise continues to be a strong tailwind, ...